MedTrace Logo

Sucrose Breath Test to Determine Intestinal Permeability in IBS

NCT01674088 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2014-02-10

No results posted yet for this study

Summary

Irritable Bowel Syndrome (IBS) is a growing clinical diagnosis affecting 10-20% of the US population. While current diagnostic criteria aids in correctly diagnosing IBS, the cause of the disease still remains unclear. It has been hypothesized that patients with IBS have alterations in the intestinal lining leading to release of toxic substances into the blood, commonly referred to as leaky gut. Current methods used to study leaky gut are both expensive and invasive. The investigators will test a new breath test to measure leaky gut in both IBS patients and subjects without IBS symptoms.

Conditions

  • Irritable Bowel Syndrome

Sponsors & Collaborators

  • University of Florida

    collaborator OTHER

  • Metabolic Solutions Inc.

    lead INDUSTRY

Principal Investigators

  • David A Wagner, PhD · Metabolic Solutions Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2012-12-31
Completion
2013-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01674088 on ClinicalTrials.gov